Lin, Yu-LinYu-LinLinKAO-LANG LIUBEEN-REN LIN2021-03-192021-03-192020-10-230025-79741536-5964https://scholars.lib.ntu.edu.tw/handle/123456789/553886Currently, the 5-year survival rate remains poor for patients with metastatic colorectal cancer (mCRC), and the purpose of therapy is to prolong survival while maintaining the quality of life. Trifluridine/tipiracil, an oral drug combining trifluorothymidine and a thymidine phosphorylase inhibitor, is indicated as salvage therapy for mCRC patients who have progressed after all available regimens. Combination of local treatments with systemic therapy such as trifluridine/tipiracil represents an apt management strategy for mCRC patients.animation[SDGs]SDG1[SDGs]SDG3pyrrolidine derivative; thymine; tipiracil; trifluridine; adenocarcinoma; aged; cancer staging; case report; drug combination; human; liver tumor; male; pathology; peritoneum tumor; quality of life; rectum tumor; salvage therapy; Adenocarcinoma; Aged; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal Neoplasms; Pyrrolidines; Quality of Life; Rectal Neoplasms; Salvage Therapy; Thymine; Trifluridinejournal article10.1097/MD.0000000000022780331207902-s2.0-85094934471https://api.elsevier.com/content/abstract/scopus_id/85094934471